Linagliptin is indicated in adult patients with type 2 diabetes mellitus (T2DM) to improve glycaemic control in conjunction with diet and exercise, as monotherapy or as add on to metformin, sulphonylureas, thiazolidinediones, insulin (with or without metformin and/or sulphonylurea), or metformin plus sulphonylureas or metformin plus empagliflozin.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
